GlassScriptPhysician profile
Alex Niu
NPI 1083020440
$6,320.28
in general payments reported to CMS, 2019-2025
25 companies · $2,792 in 2025
The $2,792 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $211 · 2021: $124 · 2022: $125 · 2023: $236 · 2024: $2,098 · 2025: $2,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,898 · Travel and Lodging: $1,718 · Consulting Fee: $1,334 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,898.46 |
| Travel and Lodging | $1,717.50 |
| Consulting Fee | $1,333.75 |
| Education | $177.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $3,099.90 | 2019-2025 | Breyanzi, Breyanzi |
| Celgene Corporation | $427.73 | 2019-2025 | Breyanzi |
| Kite Pharma, INC. | $415.93 | 2024-2025 | Yescarta |
| Dendreon Pharmaceuticals LLC | $413.29 | 2019-2020 | |
| Beone Medicines USA, INC. | $272.21 | 2025 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $223.00 | 2022-2023 | Imbruvica |
| Astrazeneca Pharmaceuticals LP | $208.39 | 2021-2025 | Calquence |
| Abbvie INC. | $184.37 | 2024-2025 | |
| Janssen Biotech, INC. | $153.19 | 2020-2023 | Imbruvica |
| Beigene USA, INC. | $144.80 | 2024 | Brukinsa |
| Merck Sharp & Dohme LLC | $125.01 | 2019 | |
| Adc Therapeutics America, INC. | $120.63 | 2025 | |
| Novartis Pharmaceuticals Corporation | $101.13 | 2019-2025 | |
| Seagen INC. | $90.01 | 2019-2025 | |
| Genentech USA, INC. | $71.63 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $54.48 | 2019-2025 | |
| Incyte Corporation | $52.34 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.09 | 2019-2020 | |
| Partner Therapeutics, INC. | $25.29 | 2019 | |
| Kyowa Kirin, INC. | $22.09 | 2020 | |
| Agios Pharmaceuticals, INC. | $19.75 | 2019 | |
| Tesaro, INC. | $19.70 | 2019 | |
| Aurobindo Pharma USA, INC. | $15.76 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.41 | 2019 | |
| Jazz Pharmaceuticals INC. | $15.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Niu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.